Skip to main content

Advertisement

Table 6 Five-year survival and crude and adjusted hazard ratios by sociodemograhic and clinical factors (n = 3,297).

From: Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1)

Characteristic 5 yr Survival1(%) Crude Hazard Ratio (95% CI)2 Adjusted3Hazard Ratio (95% CI)
Age at diagnosis      
   <60 95.06 1.00 (referent) 1.00 (referent)
   60-64 93.38 1.38 (0.86 - 2.20) 1.28 (0.80 - 2.04)
   65-69 87.92 2.59 (1.73 - 3.89) 2.10 (1.39 - 3.18)
   70-74 85.60 3.33 (2.24 - 4.95) 2.28 (1.51 - 3.46)
   75-79 74.67 6.18 (4.18 - 9.14) 3.67 (2.41 - 5.60)
   >= 80 50.82 13.00 (8.78 - 19.25) 5.29 (3.43 - 8.16)
Race/ethnicity      
   Non-Hispanic White 85.42 1.00 (referent) 1.00 (referent)
   Non-Hispanic Black 78.78 1.47 (1.18 - 1.83) 1.17 (0.92 - 1.48)
   Non-Hispanic Other 94.51 0.31 (0.10 - 0.95) 0.35 (0.11 - 1.10)
   Hispanic 92.65 0.51 (0.27 - 0.96) 0.53 (0.28 - 1.00)
   Unknown 78.25 1.40 (0.52 - 3.74) 1.29 (0.46 - 3.61)
Marital status      
   Married 86.36 1.00 (referent) 1.00 (referent)
   Not Married 78.58 1.69 (1.40 - 2.05) 1.21 (1.00 - 1.48)
   Unknown 86.39 0.90 (0.59 - 1.35) 0.67 (0.43 - 1.03)
Registry      
   California 86.03 1.00 (referent) 1.00 (referent)
   Colorado 89.97 0.79 (0.56 - 1.10) 0.94 (0.66 - 1.33)
   Illinois 82.36 1.35 (1.00 - 1.82) 1.01 (0.74 - 1.38)
   Louisiana 78.80 1.69 (1.28 - 2.25) 1.37 (1.02 - 1.84)
   New York 86.90 1.01 (0.73 - 1.40) 1.10 (0.78 - 1.54)
   Rhode Island 88.38 0.91 (0.65 - 1.27) 0.82 (0.58 - 1.16)
   South Carolina 79.79 1.72 (1.21 - 2.44) 1.54 (1.06 - 2.24)
PSA value      
   0-4 90.49 1.00 (referent) 1.00 (referent)
   >4-10 89.28 1.00 (0.69 - 1.44) 1.07 (0.73 - 1.55)
   >10-20 84.65 1.50 (1.01 - 2.21) 1.20 (0.81 - 1.79)
   20+ 75.77 2.43 (1.64 - 3.60) 1.38 (0.92 - 2.09)
   Unknown 73.16 2.65 (1.80 - 3.90) 1.82 (1.22 - 2.70)
Gleason score      
   2-4 83.90 1.00 (referent) 1.00 (referent)
   5-7 86.73 1.10 (0.81 - 1.50) 1.35 (0.98 - 1.85)
   8-10 73.69 2.21 (1.54 - 3.19) 1.96 (1.34 - 2.86)
   Unknown 74.52 2.29 (1.55 - 3.38) 1.69 (1.13 - 2.51)
Treatment      
   Radical prostatectomy 93.68 1.00 (referent) 1.00 (referent)
   Radiation therapy 85.99 2.55 (1.97 - 3.31) 1.66 (1.24 - 2.21)
   Hormonal therapy 65.24 6.75 (5.13 - 8.88) 2.83 (2.06 - 3.90)
   Watchful waiting 75.47 4.73 (3.65 - 6.14) 2.30 (1.70 - 3.12)
Comorbidity score4      
   ≤1 year post diagnosis      
   0 86.69# 1.00 (referent) 1.00 (referent)
   1 79.68# 2.84 (1.39 - 5.81) 2.16 (1.05 - 4.41)
   2+ 62.62# 9.90 (4.78 - 20.88) 6.39 (3.04 - 13.42)
   >1 to 3 years post diagnosis      
   0   1.00 (referent) 1.00 (referent)
   1   1.56 (1.08 - 2.26) 1.20 (0.83 - 1.74)
   2+   3.99 (2.52 - 6.31) 2.67 (1.68 - 4.25)
   >3 years post diagnosis      
   0   1.00 (referent) 1.00 (referent)
   1   1.48 (1.09 - 2.00) 1.22 (0.90 - 1.66)
   2+   2.16 (1.30 - 3.58) 1.47 (0.88 - 2.45)
  1. 1: 5-year survival following diagnosis conditional on having survived the first six months following diagnosis.
  2. 2: OR = odds ratio; CI = confidence interval.
  3. 3: Adjusted for factors shown in the table.
  4. 4: Hazard associated with comorbidity is time dependent.
  5. #: 5 year survival percent (not stratified by time since diagnosis)